ICA1L Activators
ICA1L Activators encompass a range of chemical compounds that act through various signaling pathways to indirectly heighten the functional activity of ICA1L. Forskolin serves as a direct stimulator of adenylyl cyclase, consequently amplifying cAMP levels within the cell, which then activates protein kinase A (PKA). The activated PKA is poised to phosphorylate ICA1L, should ICA1L be a substrate, thereby bolstering its role in cellular processes like vesicle trafficking. Similarly, Isoproterenol and Epinephrine, by engaging beta-adrenergic receptors, instigate a surge in intracellular cAMP, which, through PKA activation, could enhance the phosphorylation and function of ICA1L. Sildenafil and Vardenafil, both inhibitors of phosphodiesterase type 5 (PDE5), prevent the breakdown of cGMP, facilitating the activation of protein kinase G (PKG). PKG, if associated with ICA1L regulation, would then escalate ICA1L activity via phosphorylation. Rolipram and Cilostamide, by inhibiting PDE4 and PDE3, respectively, prevent cAMP degradation, which could lead to increased ICA1L activity through PKA-mediated phosphorylation, assuming ICA1L is involved in cAMP-dependent pathways.
Further, Anagrelide, another PDE3 inhibitor, enhances cAMP levels, potentially amplifying ICA1L activity through the same PKA-dependent mechanisms, especially in platelets but potentially in other cells as well. IBMX, as a non-selective PDE inhibitor, bolsters levels of both cAMP and cGMP, leading to activation of PKA and PKG, which may phosphorylate ICA1L, thus augmenting its activity, provided ICA1L is modulated by these pathways. FSK, by activating adenylyl cyclase, increases cAMP levels, enhancing ICA1L activity if it is a PKA substrate. Zaprinast, through inhibition of both PDE5 and PDE6, elevates cGMP levels, which could lead to the activation of PKG and subsequent enhancement of ICA1L activity if cGMP-dependent signaling mechanisms are involved.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin directly stimulates adenylyl cyclase, leading to increased levels of cyclic AMP (cAMP). Elevated cAMP activates protein kinase A (PKA), which may then phosphorylate ICA1L, thus enhancing its functional activity in processes such as vesicle trafficking or neurotransmitter release. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC). Upon activation, PKC phosphorylates target proteins involved in various signaling pathways. If ICA1L is a substrate or is regulated by PKC-mediated signaling, this would result in the enhancement of ICA1L's functional activity. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Isoproterenol is a synthetic catecholamine and non-selective beta-adrenergic agonist that elevates intracellular cAMP by activating beta-adrenergic receptors, leading to the activation of PKA. PKA could then potentially phosphorylate and activate ICA1L as part of a signaling cascade. | ||||||
(−)-Epinephrine | 51-43-4 | sc-205674 sc-205674A sc-205674B sc-205674C sc-205674D | 1 g 5 g 10 g 100 g 1 kg | $41.00 $104.00 $201.00 $1774.00 $16500.00 | ||
Epinephrine, also known as adrenaline, is an endogenous catecholamine that stimulates both alpha and beta-adrenergic receptors, leading to PKA activation via cAMP elevation. Activated PKA may enhance the functional activity of ICA1L by phosphorylation, affecting neurotransmitter release or synaptic plasticity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of PDE4, an enzyme that breaks down cAMP. Inhibition of PDE4 prevents cAMP degradation, leading to higher intracellular levels and subsequent activation of PKA. PKA, in turn, can enhance ICA1L activity through phosphorylation if ICA1L is regulated by cAMP-dependent pathways. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide is a selective PDE3 inhibitor that leads to an increase in cAMP levels by preventing its breakdown. The accumulation of cAMP activates PKA, which may phosphorylate and enhance the functional activity of ICA1L if it is part of cAMP-dependent signaling pathways. | ||||||
Anagrelide hydrochloride | 58579-51-4 | sc-203513 sc-203513A | 10 mg 50 mg | $103.00 $587.00 | 1 | |
Anagrelide is another PDE3 inhibitor that increases cAMP levels, potentially leading to PKA activation. PKA may then phosphorylate ICA1L, enhancing its activity if ICA1L operates within cAMP-dependent signaling pathways, particularly in platelets but could logically be extrapolated to other cell types. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, raising overall cAMP and cGMP levels in cells. This broad increase in cyclic nucleotides can lead to the activation of PKA or PKG, which may then enhance ICA1L activity through phosphorylation, assuming ICA1L is functionally modulated by these pathways. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast inhibits PDE5 and PDE6, resulting in elevated cGMP levels, which can activate PKG. PKG, in turn, might enhance the activity of ICA1L through phosphorylation if ICA1L is influenced by cGMP-dependent signaling mechanisms, such as those involved in neuronal signaling or synaptic function. | ||||||
Vardenafil | 224785-90-4 | sc-362054 sc-362054A sc-362054B | 100 mg 1 g 50 g | $526.00 $735.00 $16653.00 | 7 | |
Vardenafil, a PDE5 inhibitor, increases cGMP levels, potentially leading to PKG activation. PKG may then phosphorylate and enhance ICA1L | ||||||